<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Because of the progressive nature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, basal insulin alone may not be able to provide sufficient glycemic control over the long term, and thus insulin regimens will typically need to be intensified--especially for controlling postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> requiring more intensive intervention, insulin analog premix formulations can offer a simple, effective, and convenient option for tighter management of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in lieu of a traditional basal-bolus regimen </plain></SENT>
</text></document>